Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Aminophylline to Prevent Acute Kidney Injury in Children After Cardiac Surgery (KIDPROAM)

This study has been completed.
Information provided by (Responsible Party):
David Axelrod, Stanford University Identifier:
First received: November 19, 2010
Last updated: June 3, 2015
Last verified: June 2015
Children with congenital heart defects often need cardiac surgery with cardiopulmonary bypass (the "heart-lung machine"). Approximately 35 to 50% of these children will have "acute kidney injury," or damage to the kidneys, after the procedure. We currently have few medications to prevent this kidney injury. The hypothesis of this study is that giving aminophylline after heart surgery can decrease the acute kidney injury.

Condition Intervention
Acute Kidney Injury
Drug: Aminophylline
Drug: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized Placebo Controlled Trial of Aminophylline to Prevent Acute Kidney Injury in Children After Cardiac Surgery With Cardiopulmonary Bypass

Resource links provided by NLM:

Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Acute Kidney Injury Measured by Kidney Diseases: Improving Global Outcomes (KDIGO) AKI Serum Creatinine Criteria [ Time Frame: 5 days ]
    Acute Kidney Injury measured by Kidney Diseases: Improving Global Outcomes (KDIGO) AKI Serum Creatinine criteria; KDIGO Stage is a measure of acute kidney injury.

Enrollment: 144
Study Start Date: November 2010
Study Completion Date: May 2014
Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Aminophylline
Patients to receive aminophylline 5 mg/kg IV bolus then 1.8 mg/kg IV Q6 hours
Drug: Aminophylline
5 mg/kg IV bolus then 1.8 mg/kg IV Q6 hours
Other Name: treatment
Placebo Comparator: Placebo
Normal Saline Placebo
Drug: Placebo
Normal Saline

Detailed Description:
Patients are randomized to receive aminophylline or placebo for 72 hours, in a blinded fashion. Serum theophylline levels monitor for safety of aminophylline dose. Goal theophylline levels is 5-7 mcg/ml. Laboratory results will be faxed directly to the pharmacy who will adjust subsequent aminophylline dosing to maintain appropriate theophylline levels. Urine output and serum creatinine levels will be monitored to assess acute kidney injury. Serum Neutrophil Gelatinase Associated Lipocalin (NGAL) levels will also be monitored.

Ages Eligible for Study:   up to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Less than 18 years old, undergoing cardiac surgery with bypass
  • neonates must be at least 36 weeks gestational age

Exclusion Criteria:

  • History of arrythmia or seizure, on extracorporeal membrane oxygenation (ECMO) support, already taking aminophylline/theophylline, liver failure, sepsis, on renal replacement therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01245595

United States, California
Lucile Packard Childrens' Hospital
Palo Alto, California, United States, 94304
Sponsors and Collaborators
Stanford University
Principal Investigator: david m axelrod, md Stanford University
  More Information

Responsible Party: David Axelrod, MD, Clinical Assistant Professor, Stanford University Identifier: NCT01245595     History of Changes
Other Study ID Numbers: 18977
Study First Received: November 19, 2010
Results First Received: March 31, 2015
Last Updated: June 3, 2015

Keywords provided by Stanford University:
Acute Kidney Injury (AKI)
Cardiopulmonary bypass (CPB)

Additional relevant MeSH terms:
Wounds and Injuries
Acute Kidney Injury
Renal Insufficiency
Kidney Diseases
Urologic Diseases
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Cardiotonic Agents
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Purinergic P1 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Protective Agents processed this record on April 26, 2017